What Is C-Peptide?

C-peptide (connecting peptide) is a 31-amino-acid polypeptide produced by the pancreatic beta cells as a byproduct of insulin synthesis. When proinsulin is enzymatically cleaved to form active insulin and C-peptide, both are secreted into the portal vein and then into the systemic circulation in equimolar amounts. Unlike insulin, C-peptide undergoes minimal first-pass hepatic extraction—the liver removes only about 20% of C-peptide compared to 50–70% of insulin. This difference, combined with a longer half-life of 20–30 minutes (versus 4–6 minutes for insulin), makes C-peptide a more stable and reliable marker for endogenous insulin secretion. Its measurement provides a direct, quantitative window into pancreatic beta-cell function, independent of exogenous insulin administration and largely unaffected by hepatic uptake.

Although C-peptide has no established direct role in glucose metabolism, growing evidence suggests it may possess biological activities, including binding to a specific G-protein-coupled receptor on endothelial cells, promoting nitric oxide production, and exerting anti-inflammatory effects in the microvasculature. Clinically, C-peptide levels are used to differentiate between type 1 and type 2 diabetes, assess residual beta-cell function in established diabetes, evaluate fasting hypoglycemia, and screen for insulinoma. Because C-peptide and insulin are secreted together, the test is most informative when interpreted alongside concurrent blood glucose measurements. The National Institutes of Health (NIH) resource on C-peptide physiology offers a comprehensive biochemical review.

Normal Range of C-Peptide Levels

The reference range for C-peptide depends on the assay method, laboratory, and whether the sample is taken in a fasting state or after a glucose or mixed-meal challenge. In adults with normal glucose tolerance and no insulin resistance, typical fasting values fall between 0.5–2.0 nmol/L (or 1.5–6.0 ng/mL). Stimulated levels—measured 1–2 hours after a meal or during an oral glucose tolerance test—can rise to 1.0–3.0 nmol/L (3.0–9.0 ng/mL). These ranges are guidelines; each laboratory establishes its own normative cutoffs based on the population and assay platform used, such as immunometric assays from Roche, Siemens, or Beckman Coulter.

  • Fasting C-peptide (normal): 0.5–2.0 nmol/L (or 1.5–6.0 ng/mL)
  • Stimulated C-peptide (normal): 1.0–3.0 nmol/L (or 3.0–9.0 ng/mL)

It is essential to measure C-peptide together with glucose. For example, a low C-peptide with high glucose suggests insufficient endogenous insulin (type 1 diabetes or long-standing type 2). A high C-peptide with low glucose indicates endogenous hyperinsulinemia (insulinoma, sulfonylurea effect). The Mayo Clinic’s guide to C-peptide testing provides further interpretation context.

Interpreting Abnormal Ranges

A C-peptide level above normal (>2.0 nmol/L fasting) may be seen in type 2 diabetes early in the course (due to insulin resistance and compensatory hypersecretion), obesity, insulinoma, or renal impairment (since C-peptide is cleared by the kidneys). Levels below normal (<0.5 nmol/L) indicate deficient beta-cell function, typical of type 1 diabetes or advanced type 2 diabetes. The test can also help distinguish between factitious hypoglycemia from exogenous insulin (low C-peptide but high insulin) versus endogenous hyperinsulinemia (high C-peptide). It is important to note that some individuals with type 2 diabetes and relative insulin deficiency may have fasting C-peptide in the low-normal range, so stimulated testing is often more informative for classifying diabetes type.

Normal C-peptide levels are not static across the lifespan. Growth, pubertal hormone surges, changes in insulin sensitivity, and age-related pancreatic remodeling all influence secretion. Clinicians must account for these variations to avoid misdiagnosis, especially when classifying diabetes in children, adolescents, and older adults.

Children and Adolescents

During childhood, insulin demand is high due to rapid growth, increasing muscle mass, and higher glucose utilization per kilogram of body weight. C-peptide levels in healthy children tend to be slightly higher than in adults. Fasting reference ranges in pediatric populations typically span 0.5–3.0 nmol/L, though some assays report upper limits up to 3.5 nmol/L. During puberty, insulin resistance increases transiently due to elevations in growth hormone and sex steroids, leading to further compensatory hyperinsulinemia and a rise in C-peptide. This physiological change can complicate diabetes classification in adolescents: a low or low-normal C-peptide in a lean adolescent with hyperglycemia strongly supports type 1 diabetes, whereas a high C-peptide may suggest type 2 diabetes with insulin resistance. However, because obese adolescents may also have high C-peptide, autoantibody testing and C-peptide-to-glucose ratios are often necessary. A 2023 study in the Journal of Clinical Endocrinology & Metabolism established pediatric norms using new assays. For reference, see Pediatric C-peptide reference intervals.

Adults

In healthy adults aged 18–60, fasting C-peptide levels stabilize within the 0.5–2.0 nmol/L range. However, body composition significantly influences secretion: individuals with higher body mass index (BMI) and greater insulin resistance produce more insulin to maintain normoglycemia, resulting in C-peptide values at the higher end of normal or even mildly supranormal. The metabolic syndrome—characterized by abdominal obesity, dyslipidemia, and hypertension—is associated with fasting C-peptide levels above 2.0 nmol/L in many clinical populations. Conversely, lean, insulin-sensitive adults often have C-peptide values in the lower half of the reference interval. Pregnancy induces a state of progressive insulin resistance mediated by placental hormones such as human placental lactogen and tumor necrosis factor-alpha. C-peptide levels rise physiologically during the second and third trimesters, with stimulated levels sometimes exceeding non-pregnant ranges by 50%. This normal adaptation should not be misinterpreted as a sign of diabetes unless glucose levels are concurrently elevated. Postpartum, C-peptide usually returns to pre-pregnancy levels within several weeks.

Older Adults

Aging is accompanied by changes in pancreatic islet morphology and function. Most studies show that fasting C-peptide levels decline gradually after age 65–70, reflecting a reduction in beta-cell mass and secretory capacity. However, this decline is not universal—obesity, physical inactivity, and age-related insulin resistance can keep C-peptide levels elevated, even into the 9th decade. Research from the Diabetes Care longitudinal cohort indicates that some older adults maintain robust beta-cell function if they remain lean and active. In clinical practice, an older adult with a C-peptide below 0.3 nmol/L and hyperglycemia likely requires insulin therapy, while one with preserved C-peptide (>0.6 nmol/L) may respond well to oral agents. It is important to note that renal function declines with age, and since C-peptide is renally cleared, mild to moderate chronic kidney disease (CKD) can falsely elevate C-peptide levels. Clinicians should estimate glomerular filtration rate (eGFR) when interpreting C-peptide in older patients; an eGFR-adjusted interpretation or consultation with the laboratory may be needed.

Factors Affecting C-Peptide Levels

Several variables influence C-peptide independently of beta-cell function, and awareness of these factors is critical for accurate interpretation:

  • Renal function: C-peptide is cleared by the kidney; impaired renal function (eGFR <60 mL/min/1.73 m²) leads to accumulation and artefactually elevated levels. In patients with end-stage renal disease, C-peptide may be elevated two- to threefold above true secretion rates.
  • Medications: Sulfonylureas and meglitinides stimulate endogenous insulin secretion, raising C-peptide. Exogenous insulin suppresses endogenous production via negative feedback, lowering C-peptide. Glucocorticoids cause insulin resistance and may increase C-peptide. GLP-1 receptor agonists and DPP-4 inhibitors enhance glucose-dependent insulin secretion and can increase postprandial C-peptide.
  • Blood glucose level: Acute hyperglycemia stimulates insulin secretion; non-fasting samples give higher C-peptide than fasting samples. For standardized assessment, fasting or a mixed-meal challenge is preferred.
  • Pancreatic health: Pancreatitis, pancreatectomy, cystic fibrosis, or pancreatic cancer damages beta-cells, reducing secretion. Hemochromatosis with iron deposition in the pancreas also impairs beta-cell function.
  • Autoimmunity: Presence of islet autoantibodies (GAD, IA-2, ZnT8) in type 1 diabetes leads to progressive beta-cell loss and declining C-peptide over time. C-peptide measurement is used to monitor residual beta-cell mass in clinical trials.
  • Obesity and insulin resistance: Adipose tissue-derived factors such as free fatty acids, adipokines, and inflammatory cytokines increase insulin demand; higher C-peptide is seen even with normal glucose tolerance. Hyperinsulinemic-euglycemic clamp studies show a clear positive correlation between fasting C-peptide and insulin resistance indices like HOMA-IR.
  • Diet and timing: A high-carbohydrate meal stimulates more insulin and C-peptide. Standardized testing after an 8-hour fast or using a mixed-meal tolerance test (e.g., Boost or Ensure) is recommended for reproducibility.
  • Hemolysis: Hemolyzed blood samples can falsely lower C-peptide values due to release of proteolytic enzymes; repeat collection is advised if visible hemolysis is present.

Clinical Applications of C-Peptide Measurement

The C-peptide test is a cornerstone of endocrine diagnostics, with several well-established clinical applications:

  • Differentiating diabetes types: Adults presenting with diabetes can be classified by C-peptide: low (<0.2 nmol/L fasting) suggests type 1 diabetes or latent autoimmune diabetes in adults (LADA), while high or normal (≥0.6 nmol/L fasting) suggests type 2 diabetes. A stimulated C-peptide <0.3 nmol/L after a mixed meal is a strong confirmatory marker for type 1 diabetes. The ADA and EASD recommend C-peptide testing for classification when clinical features are ambiguous.
  • Monitoring residual secretion: In established type 1 diabetes, preserved C-peptide (even >0.1 nmol/L) is associated with better glycemic control, less hypoglycemia, and reduced microvascular complications. Many clinical trials of beta-cell preservation therapies (e.g., teplizumab, anti-CD3 antibodies) use stimulated C-peptide area under the curve as a primary endpoint.
  • Evaluating hypoglycemia: In unexplained hypoglycemia, simultaneous measurement of glucose, insulin, and C-peptide is essential. Exogenous insulin use (e.g., factitious or therapeutic) shows low C-peptide with high insulin, while endogenous hyperinsulinemia (insulinoma or sulfonylurea misuse) shows high C-peptide with high insulin. A 72-hour supervised fast is the gold standard for diagnosing insulinoma, with diagnostic criteria: C-peptide ≥0.6 nmol/L, insulin ≥3 µU/mL, glucose <2.8 nmol/L.
  • Screening for insulinoma: A fasting C-peptide >1.0 nmol/L with glucose <3.9 mmol/L and insulin >3 µU/mL is highly suggestive. In patients with negative imaging, selective arterial calcium stimulation with hepatic venous sampling can localize the tumor.
  • Assessing beta-cell function in pancreatic disease: In chronic pancreatitis and cystic fibrosis-related diabetes, C-peptide helps quantify residual insulin secretion and guides insulin therapy decisions.

For a clinical algorithm, the Endocrine Society’s guidelines on hypoglycemia offer evidence-based recommendations.

Testing and Interpretation

C-peptide is measured from a blood sample, usually in the morning after an 8-hour fast. For stimulated assessment, a standard mixed-meal tolerance test (e.g., 237 mL of Boost or Ensure liquid) is preferred; the sample is drawn 90 minutes after the meal. Alternatively, a glucagon stimulation test (1 mg intravenous glucagon) can be used but is less standardized. Key points for accurate interpretation:

  • Paired glucose: Always interpret C-peptide in context of the simultaneous glucose level. A C-peptide of 0.8 nmol/L is normal with glucose 5.0 mmol/L but inappropriately low with glucose 12.0 mmol/L, indicating insulin deficiency.
  • Assay specificity: Modern immunometric assays (e.g., Roche Elecsys, Siemens IMMULITE) are highly specific for intact C-peptide and do not cross-react with proinsulin or insulin degradation products. However, assays may vary; always use age- and laboratory-specific reference intervals.
  • Renal function: In CKD, C-peptide values may be misleading; use an eGFR-adjusted interpretation or consult the lab. Some laboratories provide correction factors for specific assays.
  • Hemolysis: Hemolyzed samples can falsely lower C-peptide values; repeat if the sample is visibly hemolyzed.
  • Medication history: Documenting use of sulfonylureas, exogenous insulin, or medications affecting insulin sensitivity is crucial for correct interpretation.

Low C-peptide with high glucose = insulin deficiency (type 1 or advanced type 2). High C-peptide with low glucose = endogenous hyperinsulinemia. High C-peptide with high glucose = insulin resistance (type 2, obesity, metabolic syndrome). Both high C-peptide and high glucose may also be seen in renal failure. In equivocal cases, a stimulated test can clarify.

Conclusion

C-peptide is more than a simple byproduct—it is a clinically actionable biomarker that illuminates pancreatic beta-cell health and insulin secretion dynamics. Normal fasting levels generally span 0.5–2.0 nmol/L, but age, body composition, kidney function, and metabolic state significantly shift that range. Children and adolescents have higher C-peptide due to growth and pubertal insulin resistance, while older adults may show a modest decline unless overweight or sedentary. Accurate interpretation requires pairing C-peptide with glucose, considering renal clearance, and using age-appropriate reference intervals. Whether the goal is diabetes classification, hypoglycemia investigation, or monitoring residual function, C-peptide remains an indispensable tool in clinical endocrinology. For updated reference standards, consult your laboratory’s normative data and recent publications from the American Diabetes Association.